CORT (Corcept Therapeutics Inc.) Net Profit

Official company branding of Corcept Therapeutics Inc. (CORT)

Corcept Therapeutics minimizes its environmental impact by outsourcing drug production to third-party contractors. The company's operating profit reflects this approach, with 0.05 recorded as the baseline value. Management effectively protects Korlym patents, maintaining high margins. However, financial stability relies on a single product, which creates significant risks should exclusivity rights be lost.

CORT (Corcept Therapeutics) Company Net Income history from 07/04/2022 to 10/31/2026

Comprehensive metric breakdowns and analytics for Corcept Therapeutics Incorporated (CORT)

- price and consensus price forecast:
Stock Quotes Corcept Therapeutics Corp|CORT - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Corcept Therapeutics Corp|CORT - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Corcept Therapeutics|CORT - Company Book Value|Market Cap to Net Assets Ratio corcept.com|CORT - Company Total Assets
- debt and solvency information:
Debt to Capital Corcept Therapeutics|CORT - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Corcept Therapeutics Inc.|CORT - Company Aggregate Debts|Debts to Book Capitalization Corcept Therapeutics Corp|CORT - Company Long-Term Debts|Company Short-Term Debt Corcept Therapeutics|Immediate Liquidity corcept.com
- net income and valuation multiples indicators:
CORT - Company Net Income
Fundamental valuation:Corcept Therapeutics
Signature product of corcept.com

Due to the outsourcing model for the production of metabolic drugs, Corcept Therapeutics (CORT) actual profit reflects the efficiency of contract management and real cash flow. This indicator measures daily cash generation after all expenses, where any prolonged decline in the line signals falling sales and risks of capital freeze, which is critical for assessing the fundamental safety of the asset.

Direct competitors

Net Income Ascendis|MDGL (Madrigal Pharmaceuticals) - Net Profit|Net Profit rhythmtx.com|Net Income AKRO (Akero)|MTSR (Metsera, Inc.) - Final Profit|Company Net Income MoonLake Pharma MLTX|CRNX - Net Income|NewAmsterdam Pharma - Net Profit|Company Net Income soleno.life|FOLD (Amicus Therapeutics, Inc.) - Net Income|ETNB: Profit After Payment of Taxes|AGIO (Agios Pharmaceuticals Inc) - Net Profit|Net Profit Structure Corp|Net Profit MDXG|Company Net Income RZLT (rezolutebio.com)|Company Net Income Lexicon Pharmaceuticals, Inc. LXRX|MBX Biosciences, Inc. (MBX) - Company Net Income|ALT - Company Net Income|AARD: Company Net Income|SGMT: Net Profit|BIOA - Net Financial Result|Company Net Income Biomea Fusion|Quince (QNCX) - Net Financial Result|Company Net Income Fractyl (GUTS)|Net Income vtvtherapeutics.com VTVT|Net Profit ATPC (Agape ATP)|PLUR - Net Income|SYBX - Company Net Income|Company Net Income Lipocine Inc|matinasbiopharma.com (MTNB) - Company Net Income|Spruce Biosciences Inc. - Final Profit|GLTO (Galecto, Inc.) - Net Profit|Net Income carmellrx.com (CTCX)|Net Profit LUMO|ONVO - Company Net Income|Company Net Income Radius Health RDUS